Intellectual Property - June 26, 2020
Follicum receives Notice of Allowance from the US Patent Office
Follicum has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of the US patent application. The patent application covers the company’s peptides and their use for treatment of diabetes and diabetes-associated complications. The application is directed to new peptides from the company’s two peptide classes, and […]
Intellectual Property - June 23, 2020
QureTech Bio secures US patent
QureTech Bio has received preliminary approval for a patent application in the US for a drug candidate that helps treat tuberculosis. “The US is a key market for us so this news really helps strengthen our position. We are at a very exciting stage right now,” says Fredrik Almqvist, CEO of QureTech Bio. “We have […]
Intellectual Property - May 13, 2020
Follicum files international patent application
Follicum files international patent application conferring extended protection for the topical formulation of FOL-005 and other peptides. The patent application is based on new experimental data that supports the use of the formulation for peptides other than FOL-005. The formulation of FOL-005 intended for topical application on the skin has been shown to provide good […]
Intellectual Property - May 5, 2020
AroCell files new patent application
AroCell has announced that an international (PCT) application has been filed at the Swedish Patent Office (PRV) regarding the use of Thymidine kinase 1 (TK1) in predicting the presence of and diagnosing Mycoplasma pneumonia, and in the classification of respiratory infections. “This patent application opens up a new area for using TK1 besides oncology. We […]
Intellectual Property - May 5, 2020
Nordic Nanovector patent granted
Nordic Nanovector has announced the grant of a US patent covering the use of Betalutin (177Lu-satetraxetan-lilotomab) for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy (such as rituximab/RTX). The patent strengthens Nordic Nanovector’s overall patent estate around the use of Betalutin in combination with other drugs that target antigens presented on the surface […]
Intellectual Property - April 24, 2020
Spago Nanomedical’s Tumorad patent approved in Japan
Spago Nanomedical has received notice of allowance for the company’s patent application including Tumorad product protection in Japan. ”The patent covers the nanomaterial that is central for the Tumorad-project. As Japan represent a potentially large market for radionuclide therapies, this approval is important. It also underscores the quality of our innovation and strengthens the commercial […]
